Sustained IFN Signature Suppression with Anifrolumab in a SAVI patient Refractory to JAK Inhibitor and Dazukibart Therapy

IF 11.4 1区医学 Q1 RHEUMATOLOGY

Arthritis & Rheumatology Pub Date : 2025-02-25 DOI:10.1002/art.43145

Sara Alehashemi, Bjoern Buehring, Adriana A de Jesus, Sachin Gaurav, Andre Rastegar, Alexi Baumgardner, Kip Friend, Oluwatobi T. Arisa, William D. Figg, Danielle Fink, Douglas B. Kuhns, Ben Colton, Cody J Peer, Raphaela Goldbach-Mansky

引用次数: 0

Abstract

To report the efficacy and safety of interferon-β (IFNβ) neutralizing monoclonal antibody (dazukibart), followed by treatment with anti-IFNAR1 antibody (anifrolumab), in a patient with STING-associated vasculopathy with onset in infancy (SAVI) who had vasculitic ulcers and systemic inflammation refractory to Janus kinase inhibition (JAKi).

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Arthritis & Rheumatology RHEUMATOLOGY-

CiteScore

20.90

自引率

3.00%

发文量

371

期刊介绍： Arthritis & Rheumatology is the official journal of the American College of Rheumatology and focuses on the natural history, pathophysiology, treatment, and outcome of rheumatic diseases. It is a peer-reviewed publication that aims to provide the highest quality basic and clinical research in this field. The journal covers a wide range of investigative areas and also includes review articles, editorials, and educational material for researchers and clinicians. Being recognized as a leading research journal in rheumatology, Arthritis & Rheumatology serves the global community of rheumatology investigators and clinicians.